Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) rose 51.7% during mid-day trading on Thursday . The company traded as high as C$0.23 and last traded at C$0.22. Approximately 334,187 shares were traded during trading, a decline of 36% from the average daily volume of 521,379 shares. The stock had previously closed at C$0.15.
Hemostemix Trading Up 31.0 %
The stock has a fifty day moving average of C$0.20 and a 200 day moving average of C$0.12. The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04. The company has a market capitalization of C$27.69 million, a P/E ratio of -5.54 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- How to Use the MarketBeat Stock Screener
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- What is the Shanghai Stock Exchange Composite Index?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
